Human PD-1 / PDCD1 Protein, Mouse IgG2a Fc Tag (HPLC-verified)
分子別名(Synonym)
PDCD1,PD1,CD279,SLEB2
表達(dá)區(qū)間及表達(dá)系統(tǒng)(Source)
Human PD-1, Mouse IgG2a Fc Tag (PD1-H5255) is expressed from human 293 cells (HEK293). It contains AA Leu 25 - Gln 167 (Accession # Q15116-1).
Predicted N-terminus: Leu 25
蛋白結(jié)構(gòu)(Molecular Characterization)
![1.jpg 1.jpg](/SupplyImg1/2025-01-17/6387270819658295787267693.jpg)
This protein carries a mouse IgG2a Fc tag at the C-terminus.
The protein has a calculated MW of 42.5 kDa. The protein migrates as 55-66 kDa under reducing (R) condition (SDS-PAGE) due to glycosylation.
內(nèi)毒素(Endotoxin)
Less than 0.1 EU per μg by the LAL method.
純度(Purity)
>95% as determined by SDS-PAGE.
>90% as determined by SEC-HPLC.
制劑(Formulation)
Lyophilized from 0.22 μm filtered solution in PBS, pH7.4 with trehalose as protectant.
Contact us for customized product form or formulation.
重構(gòu)方法(Reconstitution)
Please see Certificate of Analysis for specific instructions.
For best performance, we strongly recommend you to follow the reconstitution protocol provided in the CoA.
存儲(chǔ)(Storage)
For long term storage, the product should be stored at lyophilized state at -20°C or lower.
Please avoid repeated freeze-thaw cycles.
This product is stable after storage at:
-20°C to -70°C for 12 months in lyophilized state;
-70°C for 12 months under sterile conditions after reconstitution.
![2.jpg 2.jpg](/SupplyImg1/2025-01-17/6387270820413168939573077.jpg)
![3.jpg 3.jpg](/SupplyImg1/2025-01-17/6387270820697045565803981.jpg)
![4.jpg 4.jpg](/SupplyImg1/2025-01-17/6387270820987278314292313.jpg)
背景(Background)
程序性細(xì)胞死亡蛋白1(PD-1)也稱為CD279和PDCD1,是一種I型膜蛋白,是T細(xì)胞調(diào)節(jié)因子CD28/CTLA-4家族的成員。PDCD1在活化的T細(xì)胞、B細(xì)胞、巨噬細(xì)胞、髓系細(xì)胞和胸腺細(xì)胞亞群的表面表達(dá)。PD-1有兩個(gè)配體,PD-L1和PD-L2,它們是B7家族的成員。經(jīng)IFN-γ治療后,PD-L1幾乎在所有小鼠腫瘤細(xì)胞系上表達(dá),包括PA1骨髓瘤、P815肥大細(xì)胞瘤和B16黑色素瘤。PD-L2的表達(dá)受到更多限制,主要由DC和少數(shù)腫瘤系表達(dá)。PD1通過抑制PI3K/AKT通路的激活和轉(zhuǎn)導(dǎo),抑制T細(xì)胞增殖和相關(guān)細(xì)胞因子的產(chǎn)生,包括IL-1、IL-4、IL-10和IFN-γ。此外,PD1的結(jié)合通過使關(guān)鍵信號(hào)轉(zhuǎn)導(dǎo)子去磷酸化來抑制BCR介導(dǎo)的信號(hào)。在體外,用PD-L1-Ig處理抗CD3刺激的T細(xì)胞會(huì)導(dǎo)致T細(xì)胞增殖和IFN-γ分泌減少。針對(duì)PD-1的單克隆抗體正在被開發(fā)用于治療癌癥,以增強(qiáng)免疫系統(tǒng)。
關(guān)鍵字: PD-1;PD-1蛋白;PD-1重組蛋白;ACRO;百普賽斯;
百普賽斯集團(tuán)ACROBiosystems Group(股票代碼:301080)是成立于2010年的跨國(guó)生物科技公司,是為全球生物醫(yī)藥、健康產(chǎn)業(yè)領(lǐng)域提供關(guān)鍵生物試劑產(chǎn)品及解決方案的行業(yè)平臺(tái)型基石企業(yè)。2021年在創(chuàng)業(yè)板上市。百普賽斯集團(tuán)業(yè)務(wù)遍布全球,橫跨亞洲、北美洲、歐洲,在中國(guó)、美國(guó)、瑞士等12個(gè)城市設(shè)有辦公室、研發(fā)中心及生產(chǎn)基地。目前累計(jì)服務(wù)客戶超6000家,與全球Top 20醫(yī)藥企業(yè)均建立了長(zhǎng)期、穩(wěn)定的合作伙伴關(guān)系。集團(tuán)旗下?lián)碛衅放艫CROBiosystems百普賽斯、bioSeedin柏思薈、Condense Capital墾拓資本和ACRODiagnostics百斯醫(yī)學(xué)等。